Sanofi unveils new data for Dupixent in children with dermatitis
Nearly three times as many children achieved clear or almost clear skin when treated with Dupixent and standard-of-care topical corticosteroids
Read More
Tag: dupilumab
Dupixent hits endpoints in paediatric trial
33% of patients who received Dupixent every four weeks achieved clear or almost clear skin.
Read More
FDA approves Dupixent, Darzalex, Soliris
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read More
Sanofi, Regeneron successful in phase II asthma trial
The investigational IL-33 antibody REGN3500 met its primary and secondary endpoints in the joint phase II proof-of-concept trial.
Read More
FDA grants Dupixent Priority Review for sinusitis
US regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps.
Read More
Priority review for Sanofi, Regeneron’s Dupixent
Sanofi and Regeneron’s biologic Dupixent has been granted a priority review in the US for use to treat certain adolescent patients with moderate-to-severe atopic dermatitis.
Read More
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all their primary and secondary endpoints.
Read More
Sanofi’s Dupixent approved for routine NHS use
Adults with moderate to severe atopic dermatitis are a step closer to being able to routinely access treatment with Sanofi’s Dupixent on the NHS, following a green light from cost regulators.
Read More
Atopic dermatitis patients to be denied NHS access to Dupixent
The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
Read More
Sanofi files Dupixent for severe asthma
US regulators have accepted for review Sanofi/Regeneron’s biologic Dupixent as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.
Read More
Sanofi, Regeneron beef up investment in immunotherapies
Sanofi and Regeneron are boosting their investment in development programmes for the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 (tissue specific) allergic diseases.
Read More
Sanofi, Regeneron’s biologic shines again in asthma trial
Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
